Biomarker ID | 926 |
PMID | 22589488 |
Year | 2012 |
Biomarker | Methylation Status Of CRIP1; RUNX3; HS3ST2; FLNC; RASGRF2 |
Biomarker Basis | Methylation Based |
Biomolecule | Methylation |
Source | Tissue |
Subjects | Humans |
Regulation | Methylated in PCA: |
Odds Ratio/Hazard Ratio/Relative Risk | NA |
Effect on Pathways | NA |
Experiment | recurrent prostate cancer Vs nonrecurrent cancer |
Type of Biomarker | Prognostic |
Cohort | 4 different sub groups of patients with prostate cancer: (i) tumor versus matched normal tissues ((ii) recurrence versus nonrecurrence (iii) clinical versus biochemical recurrence and (iv) systemic recurrence versus local recurrence. 20 patients from each group were taken |
Senstivity | NA |
Specificity | NA |
AUC | NA |
Accuracy | NA |
Level Of Significance | NA |
Method Used | Pyrosequencing |
Clinical | No |
Remarks | NA |
Clinical Trial Number | NA |
Degree Of Validity | Not validated on independent patient dataset |
Technical Name | CRIP1, RUNX3, HS3ST2, FLNC, RASGRF2 |